益生菌对肠易激综合征的干预效果和安全性评价的系统综述  

Efficacy and safety of probiotics for irritable bowel syndrome:a systematic review

作　　者：赵霄扬 胡馨月 赵奥星 赵熙怡 毛祉懿 逯畅 李雨辰[2] 沈曦[1] Zhao Xiaoyang;Hu Xinyue;Zhao Aoxing;Zhao Xiyi;Mao Zhiyi;Lu Chang;Li Yuchen;Shen Xi(Department of Nutrition and Food Hygiene,West China School of Public Health/West China Fourth Hospital,Sichuan University,Chengdu 610041,China;Department of Mental Health Center,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西公共卫生学院营养与食品卫生学系,成都610041 [2]四川大学华西医院心理卫生中心,成都610041

出　　处：《中华临床营养杂志》2025年第1期72-80,共9页Chinese Journal of Clinical Nutrition

基　　金：四川省自然科学基金(青年基金)(2023NSFSC1487)。

摘　　要：肠易激综合征(irritable bowel syndrome,IBS)是一种常见的肠道功能紊乱性疾病,其症状会受到肠道微生物群组成的影响。益生菌改善IBS的确切机制尚不完全清楚,临床应用亦缺乏统一的标准。本文检索了2020年1月至2023年12月公开发表的国内外文献,共纳入12篇关于益生菌改善IBS的随机对照试验(RCT)文献进行证据性评价的系统综述,以评估益生菌对IBS的改善效果和安全性。与安慰剂相比,益生菌制剂能够改善IBS患者的总体疗效,患者对相关菌株的耐受性良好,提示益生菌具备对IBS进行干预的潜力。不同的益生菌菌株、剂量、组合方式和用药时机均会对干预效果产生影响。未来仍需开展大规模、多中心、长期的随访研究,以明确有效的菌株及其使用方法,推动益生菌在IBS治疗中的应用。Irritable bowel syndrome(IBS)is a common functional gastrointestinal disorder and its symptoms are subject to the composition of the gut microbiota.However,it is not yet clear how probiotics relieve IBS,and there is no well-acknowledged standards concerning the clinical application of probiotics.This systematic review was conducted on the literature published from January 2020 to December 2023 and included 12 randomized controlled trials on probiotics in the treatment of IBS.Compared with placebo,the probiotic preparations improved the overall efficacy in IBS patients and was also well tolerated,suggesting the potential of probiotics in IBS management.Nevertheless,different probiotic strains,dosages,combinations,and dosing schedules may affect the outcomes.In the future,large-scale,multi-center,long-term follow-up studies are still needed to clarify the effective strains and methods of use and to promote the use of probiotics in the treatment of IBS.

关 键 词：肠易激综合征 益生菌 肠道菌群 随机对照试验 

分 类 号：R574.4[医药卫生—消化系统]